Infraredx, Inc., a Nipro company, is advancing the diagnosis and management of coronary artery
disease by providing cardiologists with the most precise imaging tools required to predict and
ultimately prevent heart attacks. Its Makoto™ Intravascular Imaging System, with
accompanying Dualpro™ IVUS+NIRS catheter, is the only technology on the market that is
FDA-cleared for the detection of lipid core plaque (LCP). LCP, suspected to be vulnerable
plaque, is well-documented in studies as the cause of most serious heart attacks. Infraredx is
dedicated to advancing this important field of research and conducting landmark clinical trials to
transform how we view and treat heart disease. Come by booth #758 for a demo of the Makoto Imaging System.